Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Clinical Services: To outsource or To Not Outsource, That Is the Question

When providers think of purchased services, their minds typically go to facility support, IT, and ancillary services. However, this  scope is too limited and doesn’t encompass the full breadth of what falls under the definition of purchased services. The fact is, there are over 250 clinical services that are categorized as a purchased service including pharmacy compounding…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

When providers think of purchased services, their minds typically go to facility support, IT, and ancillary services. However, this scope is too limited and doesn’t encompass the full breadth of what falls under the definition of purchased services. The fact is, there are over 250 clinical services that are categorized as a purchased service including pharmacy compounding services, dialysis services, imaging services, and neurology services.

Another way to describe this is to say that all “clinical services” could potentially be a purchased service, but are not necessarily the the most commonly known purchased services categories such as lawn care, medical waste disposal, or courier services that hospital administrators typically outsource. Because clinical services can be performed by skilled clinicians within the hospital, it can be challenging for healthcare organization leaders to determine whether or not outsourcing these types of services will affect quality of care and ultimately the total costs to serve patients.

Let’s take a closer look at the items found under the “clinical services” umbrella and identify both the questions to ask and typical tasks to perform to determine whether or not they should be outsourced. As with all decisions involving purchased services, but perhaps even more so with services that fall under the clinical category, the goal of choosing to outsource, is to help your healthcare organization save money while continuing to provide the high standard of care your patients expect.

  1. Start by comparing costs: Clinical services, like other purchased services categories, must be either outsourced or performed by facility personnel. Many providers should begin by comparing department profit and loss versus an outsourced firm’s cost model to determine what makes the most sense for each given department. There will likely not be a one-size-fits-all
  1. Perform clinical oversight: Though other purchased services areas may need little oversight, clinical services that are outsourced will need regular and rigorous clinical oversight to ensure they run smoothly and consistently attain the desired results. Department leaders in clinical areas must perform regular analysis of an outsourced firm’s results to determine whether their costs and patient outcomes have changed. Incorporating these data points into regularly scheduled Value Analysis Team (VAT) meetings will ensure consistent quality and outcomes.
  1. Find out if your outsourced firm has best-in-class results:Providers that outsource clinical areas are attempting to obtain the scale and best practices of the outsourced firm. Therefore, it is imperative that clinical leaders and supply chain leaders leverage the data and scale of their outsourced firm to achieve best-in-class results and continuous improvement. Don’t settle for “good enough.”
  1. Schedule regular reviews: Setting an outsourced service on autopilot won’t yield stellar results. Partnering with the outsourced service provider to review optimization opportunities and key performance data will help with continuous improvement and determine that the value of outsourcing isn’t falling away over time.

Every year, hospitals in America waste more than $50 billion on healthcare purchased services—including clinical services. Uncover millions in savings easier and faster with Valify. Valify is the only 100% dedicated web-based solution that allows healthcare organizations to quickly identify, benchmark and track savings in hospital purchased services.

Read more at getvalify.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512